Novo Nordisk, Wegovy and obesity
Data on new Novo Nordisk obesity drug disappoints in trial, shares drop
Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate CagriSema, knocking shares and stoking worries that rival Eli Lilly may be gaining an edge over the company in the weight-loss drugs market.
Verywell Health on MSN3d
Novo Nordisk Offers Wegovy for $499 a Month in Direct-to-Consumer ProgramFact checked by Nick Blackmer Novo Nordisk launched a direct-to-consumer program last week to sell Wegovy at a reduced price ...
Novo Nordisk is providing direct-to-patient delivery of Wegovy (semaglutide) through the NovoCare Pharmacy program.
9don MSN
The pharmacy, called NovoCare, will allow patients to pay $499 in cash per month for the blockbuster weight loss drug.
Novo Nordisk said on Wednesday it would begin selling its weight-loss drug Wegovy at a discounted price of $499 per month to ...
Novo Nordisk said it will offer all doses of Wegovy for $499 a month to patients paying cash, a bid to reach consumers who ...
The weight-loss drug can cost patients more than $1,000 a month if they do not have health insurance coverage.
Novo Nordisk is cutting the price of its weight-loss drug, Wegovy, and selling it through a direct-to-patient online pharmacy ...
Europe’s largest pharmaceutical firm, Novo Nordisk, has announced that it will offer its most popular weight-loss drug, Wegovy, for less than half of its listed price. This follows a similar ...
The setback comes at a crucial time for Novo Nordisk, which had positioned CagriSema as its next-generation weight-loss ...
Novo Nordisk (NVO), the company behind popular diabetes and obesity treatments Ozempic and Wegovy, saw its stock rise on Thursday after ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback